Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF U.S. OPTIC NEURITIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
7 PIPELINE ANALYSIS
8 U.S. OPTIC NEURITIS MARKET: REGULATIONS
8.1 REGULATION IN THE U.S.:
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISING PREVALENCE OF EYE DISORDERS
9.1.2 INCREASE IN AGING POPULATION
9.1.3 RISE IN TRAUMATIC INJURIES
9.2 RESTRAINTS
9.2.1 HIGH COST ASSOCIATED WITH OPTIC NERVE DISORDERS TREATMENT
9.2.2 RISKS ASSOCIATED WITH VARIOUS TREATMENTS METHODS
9.3 OPPORTUNITIES
9.3.1 RISE IN HEALTHCARE EXPENDITURE
9.3.2 STRATEGIC INITIATIVES OF KEY PLAYERS
9.4 CHALLENGES
9.4.1 NEGATIVE EFFECTS OF SYSTEMIC STEROIDS
9.4.2 LACK OF AWARENESS AMONG PEOPLE REGARDING DIFFERENT EYE TREATMENTS
10 U.S. OPTIC NEURITIS MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 CORTICOSTEROIDS
10.2.1 METHYLPREDNISOLONE
10.2.2 PREDNISONE
10.2.3 OTHERS
10.3 IV IMMUNOGLOBULIN
10.4 SUPPLEMENTS
10.5 OTHERS
11 U.S. OPTIC NEURITIS MARKET, BY DIAGNOSIS
11.1 OVERVIEW
11.2 MRI SCAN
11.3 BLOOD TEST
11.4 OCULAR COHERENCE TOMOGRAPHY
11.5 LUMBAR PUNCTURE
11.6 OTHERS
12 U.S. OPTIC NEURITIS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.3 ORAL
13 U.S. OPTIC NEURITIS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CLINICS
13.4 ACADEMIC AND RESEARCH INSTITUTES
13.5 OTHERS
14 U.S. OPTIC NEURITIS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 OTHERS
15 U.S. OPTIC NEURITIS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: UNITED STATES
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 PFIZER INC.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENT
17.2 NOVARTIS AG
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 PRODUCT PORTFOLIO
17.2.4 RECENT DEVELOPMENT
17.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 VIATRIS INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 PRODUCT PORTFOLIO
17.4.4 RECENT DEVELOPMENT
17.5 BAUSCH & LOMB INCORPORATED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENTS
17.6 BRISTOL – MYERS SQUIBB COMPANY
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 FRESENIUS KABI USA
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 ABBVIE INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ADVACAREPHARMA
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 AKORN OPERATING COMPANY LLC.
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 AMNEAL PHARMACEUTICALS LLC
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 GSK PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 HIKMA PHARMACEUTICALS PLC
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 JUBILANT CADISTA
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 MERCK & CO., INC.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 NOVITIUM PHARMA
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 ACCURE THEREPEUTICS
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 ACORDA THERAPEUTICS INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 BIOGEN INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 MALLINCKRDOT PHARMACEUTICALS
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENT
17.22 NOVEOME BIOTHERAPEUTICS, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 SANOFI
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 U.S. OPTIC NEURITIS MARKET, PIPELINE ANALYSIS
TABLE 2 U.S. OPTIC NEURITIS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 3 U.S. OPTIC NEURITIS MARKET, BY TREATMENT, 2020-2029 (VOLUME IN MILLION)
TABLE 4 U.S. CORTICOSTEROIDS IN OPTIC NEURITIS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 5 U.S. OPTIC NEURITIS MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)
TABLE 6 U.S. OPTIC NEURITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 7 U.S. OPTIC NEURITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 8 U.S. OPTIC NEURITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 U.S. OPTIC NEURITIS MARKET: SEGMENTATION
FIGURE 2 U.S. OPTIC NEURITIS MARKET: DATA TRIANGULATION
FIGURE 3 U.S. OPTIC NEURITIS MARKET: DROC ANALYSIS
FIGURE 4 U.S. OPTIC NEURITIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 U.S. OPTIC NEURITIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 U.S. OPTIC NEURITIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 U.S. OPTIC NEURITIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 U.S. OPTIC NEURITIS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 U.S. OPTIC NEURITIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 U.S. OPTIC NEURITIS MARKET: SEGMENTATION
FIGURE 11 THE INCREASING PREVALENCE OF EYE DISORDERS AND RISE IN THE GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE U.S. OPTIC NEURITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. OPTIC NEURITIS MARKET IN 2022 AND 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. OPTIC NEURITIS MARKET
FIGURE 14 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, 2021
FIGURE 15 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 16 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 17 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, 2021
FIGURE 19 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)
FIGURE 20 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, CAGR (2022-2029)
FIGURE 21 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, LIFELINE CURVE
FIGURE 22 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 24 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 U.S. OPTIC NEURITIS MARKET: BY END USER, 2021
FIGURE 27 U.S. OPTIC NEURITIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 28 U.S. OPTIC NEURITIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 29 U.S. OPTIC NEURITIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 31 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 32 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 33 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 U.S. OPTIC NEURITIS MARKET: COMPANY SHARE 2021 (%)
